<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436201</url>
  </required_header>
  <id_info>
    <org_study_id>11550</org_study_id>
    <secondary_id>H9X-MC-GBCR</secondary_id>
    <nct_id>NCT01436201</nct_id>
  </id_info>
  <brief_title>A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants</brief_title>
  <official_title>Effect of Dulaglutide (LY2189265) on the Pharmacokinetics of Digoxin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study how the body processes digoxin and the effect of&#xD;
      dulaglutide on how digoxin is processed by the body. Information about any side effects that&#xD;
      may occur will also be collected.&#xD;
&#xD;
      This study is for research purposes only and is not intended to treat any medical condition.&#xD;
      This research study requires that a blood sample be obtained and stored for future research&#xD;
      involving genetic analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Digoxin</measure>
    <time_frame>Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Digoxin</measure>
    <time_frame>Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin</measure>
    <time_frame>Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Digoxin + Dulaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digoxin: Two 0.5-milligram (mg) doses, oral, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, oral, once daily on Day 2 to Day 17.&#xD;
Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Digoxin + Dulaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered as subcutaneous injection</description>
    <arm_group_label>Digoxin + Dulaglutide</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy males or females, as determined by medical history and physical&#xD;
             examination&#xD;
&#xD;
          -  Male participants with female partners of child-bearing potential, or partners who are&#xD;
             pregnant or breastfeeding, agree to use a reliable method of contraception from the&#xD;
             time of the first dose until 3 months after the last dose of investigational product,&#xD;
             as determined by the investigator. The method may be one of the following:&#xD;
&#xD;
               -  Condom with spermicidal agent&#xD;
&#xD;
               -  Male participant sterilization&#xD;
&#xD;
               -  True abstinence (which is in line with the participant's usual lifestyle choice;&#xD;
                  withdrawal or calendar methods are not considered acceptable)&#xD;
&#xD;
          -  Female participants not of child-bearing potential (that is, they are postmenopausal&#xD;
             or permanently sterilized [such as, tubal occlusion, hysterectomy, bilateral&#xD;
             salpingectomy]). Such participants will not be required to use contraception but must&#xD;
             test negative for pregnancy at the time of enrolment. Postmenopausal is defined as at&#xD;
             least 1 year post cessation of menses (without an alternative medical cause) or at&#xD;
             least 1 year of spontaneous amenorrhea, with follicle stimulating hormone (FSH) ≥40&#xD;
             milli-international units per milliliter (mIU/mL)&#xD;
&#xD;
          -  Female participants who have undergone sterilization by tubal ligation agree to use a&#xD;
             condom in conjunction with spermicidal gel, foam, cream, film or suppository from the&#xD;
             time of screening until 3 months after the last dose of investigational product. Such&#xD;
             participants must also test negative for pregnancy at the time of enrolment&#xD;
&#xD;
          -  Have a body mass index (BMI) of 18.5 to 32.0 kilogram per square meter (kg/m^2),&#xD;
             inclusive, at screening&#xD;
&#xD;
          -  Have clinical laboratory test results within normal reference range for the population&#xD;
             or investigator site, or results with acceptable deviations that are judged to be not&#xD;
             clinically significant by the investigator (potassium, magnesium, and calcium values&#xD;
             must be within the normal range)&#xD;
&#xD;
          -  Have normal renal function defined as an estimated creatinine clearance (CrCl) of ≥80&#xD;
             milliliter per minute (mL/min)&#xD;
&#xD;
          -  Have venous access sufficient to allow for blood sampling&#xD;
&#xD;
          -  Are reliable and willing to make themselves available for the duration of the study&#xD;
             and are willing to follow study restrictions&#xD;
&#xD;
          -  Have given written informed consent approved by Lilly and the ethical review board&#xD;
             (ERB) governing the site&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are currently enrolled in, have completed or discontinued within the last 30 days&#xD;
             from, a clinical trial involving an investigational product, or are concurrently&#xD;
             enrolled in any other type of medical research judged not to be scientifically or&#xD;
             medically compatible with this study&#xD;
&#xD;
          -  Have known allergies to glucagon like peptide-1 (GLP-1)-related compounds including&#xD;
             dulaglutide (LY2189265) or to digoxin, related compounds or any components of either&#xD;
             formulation&#xD;
&#xD;
          -  Are participants who have previously completed or withdrawn from this study or any&#xD;
             other study investigating dulaglutide in the 3 months prior to screening or have&#xD;
             received glucagon-like peptides or incretin mimetics in the 3 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Have an abnormality in the 12-lead electrocardiogram (ECG) (such as, first, second, or&#xD;
             third degree atrioventricular [AV] block, prolonged corrected QT [QTc] interval, sinus&#xD;
             tachycardia, sinus bradycardia, atrial fibrillation, or sinus node disease) that, in&#xD;
             the opinion of the investigator, increases the risks associated with participating in&#xD;
             the study&#xD;
&#xD;
          -  Have a history of significant dysrhythmias or AV block&#xD;
&#xD;
          -  Have an abnormal blood pressure (after at least 5 minutes sitting) that, in the&#xD;
             opinion of the investigator, increases the risks associated with participating in the&#xD;
             study&#xD;
&#xD;
          -  Have a history or presence of cardiac, respiratory, hepatic, renal, endocrine (such&#xD;
             as, hypothyroidism), hematological, or neurological disorders capable of significantly&#xD;
             altering the absorption, metabolism, or elimination of drugs; of constituting a risk&#xD;
             when taking the study medication; or of interfering with the interpretation of data&#xD;
&#xD;
          -  Have a history or presence of pancreatitis (history of chronic pancreatitis or&#xD;
             idiopathic acute pancreatitis) or gastrointestinal disorder, for example relevant&#xD;
             esophageal reflux or gall bladder disease, or any gastrointestinal disease which&#xD;
             impacts gastric emptying (GE) (such as, gastric bypass surgery, pyloric stenosis, with&#xD;
             the exception of appendectomy) or could be aggravated by GLP-1 analogs. Participants&#xD;
             with dyslipidemia, and participants who had cholecystolithiasis (removal of gall&#xD;
             stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further&#xD;
             sequelae, may be included in the study at the discretion of the screening physician&#xD;
&#xD;
          -  Show evidence of significant active neuropsychiatric disease&#xD;
&#xD;
          -  Have family history of medullary thyroid cancer (MTC) or a genetic condition that&#xD;
             predisposes to MTC&#xD;
&#xD;
          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug&#xD;
             screening&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human&#xD;
             HIV antibodies&#xD;
&#xD;
          -  Show evidence of hepatitis C and/or positive hepatitis C antibody&#xD;
&#xD;
          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen&#xD;
&#xD;
          -  Are women with a positive pregnancy test or women who are lactating&#xD;
&#xD;
          -  Have used or intend to use over-the-counter medication other than acetaminophen within&#xD;
             7 days prior to dosing or prescription medication (with the exception of&#xD;
             vitamin/mineral supplements) within 14 days prior to dosing, or have used St John's&#xD;
             Wort within 14 days prior to dosing&#xD;
&#xD;
          -  Have donated blood of more than 500 mL within the month prior to screening&#xD;
&#xD;
          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) 14 units&#xD;
             per week (females), or are unwilling to stop alcohol consumption from screening&#xD;
             through follow-up (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine;&#xD;
             1.5 oz or 45 mL of distilled spirits)&#xD;
&#xD;
          -  Are smokers&#xD;
&#xD;
          -  Have a history of cancer with the past 20 years, with the exception of basal cell or&#xD;
             squamous cell skin cancer, or treated cervical carcinoma in situ&#xD;
&#xD;
          -  Intend to consume grapefruit within 7 days prior to dosing&#xD;
&#xD;
          -  Are participants who, in the opinion of the investigator, are in any way unsuitable to&#xD;
             participate in the study&#xD;
&#xD;
          -  Have any medical conditions, medical history or are taking any medication which are&#xD;
             contraindicated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <results_first_submitted>October 3, 2014</results_first_submitted>
  <results_first_submitted_qc>October 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 7, 2014</results_first_posted>
  <last_update_submitted>October 3, 2014</last_update_submitted>
  <last_update_submitted_qc>October 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Digoxin + Dulaglutide</title>
          <description>Digoxin: Two 0.5-milligram (mg) doses, administered orally, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, orally, once daily on Day 2 to Day 17.&#xD;
Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Digoxin + Dulaglutide</title>
          <description>Digoxin: Two 0.5-milligram (mg) doses, administered orally, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, orally, once daily on Day 2 to Day 17.&#xD;
Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Digoxin</title>
        <time_frame>Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17</time_frame>
        <population>Participants who received at least one dose of study drug (digoxin or dulaglutide) with evaluable digoxin AUC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Digoxin Only</title>
            <description>Digoxin: Two 0.5-milligram (mg) doses, administered orally, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, orally, once daily on Day 2 to Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Digoxin + Dulaglutide</title>
            <description>Digoxin: Two 0.5-milligram (mg) doses, administered orally, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, orally, once daily on Day 8 to Day 17.&#xD;
Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Digoxin</title>
          <population>Participants who received at least one dose of study drug (digoxin or dulaglutide) with evaluable digoxin AUC data.</population>
          <units>nanograms times hours/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="25"/>
                    <measurement group_id="O2" value="NA" spread="NA">Participants had not received dulaglutide dose at Day 7.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Participants received digoxin + dulaglutide dose at Day 10 (not digoxin only).</measurement>
                    <measurement group_id="O2" value="16.1" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17 (n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Participants received digoxin + dulaglutide dose at Day 17 (not digoxin only).</measurement>
                    <measurement group_id="O2" value="16.3" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Digoxin</title>
        <time_frame>Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17</time_frame>
        <population>Participants who received at least one dose of study drug (digoxin or dulaglutide) with evaluable digoxin Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>Digoxin Only</title>
            <description>Digoxin: Two 0.5-milligram (mg) doses, administered orally, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, orally, once daily on Day 2 to Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Digoxin + Dulaglutide</title>
            <description>Digoxin: Two 0.5-milligram (mg) doses, administered orally, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, orally, once daily on Day 8 to Day 17.&#xD;
Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Digoxin</title>
          <population>Participants who received at least one dose of study drug (digoxin or dulaglutide) with evaluable digoxin Cmax data.</population>
          <units>nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="27"/>
                    <measurement group_id="O2" value="NA" spread="NA">Participants had not received dulaglutide dose at Day 7.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Participants received digoxin + dulaglutide dose at Day 10 (not digoxin only).</measurement>
                    <measurement group_id="O2" value="1.34" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17 (n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Participants received digoxin + dulaglutide dose at Day 17 (not digoxin only).</measurement>
                    <measurement group_id="O2" value="1.42" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin</title>
        <time_frame>Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17</time_frame>
        <population>Participants who received at least one dose of study drug (digoxin or dulaglutide) with evaluable digoxin Tmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>Digoxin Only</title>
            <description>Digoxin: Two 0.5-milligram (mg) doses, administered orally, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, orally, once daily on Day 2 to Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Digoxin + Dulaglutide</title>
            <description>Digoxin: Two 0.5-milligram (mg) doses, administered orally, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, orally, once daily on Day 8 to Day 17.&#xD;
Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin</title>
          <population>Participants who received at least one dose of study drug (digoxin or dulaglutide) with evaluable digoxin Tmax data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Participants had not received dulaglutide dose at Day 7.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Participants received digoxin + dulaglutide dose at Day 10 (not digoxin only).</measurement>
                    <measurement group_id="O2" value="1.50" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17 (n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Participants received digoxin + dulaglutide dose at Day 17 (not digoxin only).</measurement>
                    <measurement group_id="O2" value="1.50" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Digoxin</title>
          <description>Digoxin: Two 0.5-milligram (mg) doses, administered orally, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, orally, once daily on Day 2 to Day 7.</description>
        </group>
        <group group_id="E2">
          <title>Digoxin + Dulaglutide</title>
          <description>Digoxin: Two 0.5-milligram (mg) doses, administered orally, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, orally, once daily on Day 8 to Day 17.&#xD;
Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vessel puncture site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyperlipasaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

